Detalles de la búsqueda
1.
Cardiovascular Safety of Testosterone-Replacement Therapy.
N Engl J Med
; 389(2): 107-117, 2023 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37326322
2.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644155
3.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644154
4.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Lancet
; 399(10341): 2113-2128, 2022 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644166
5.
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Gastroenterology
; 162(7): 1891-1910, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35227777
6.
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Gastroenterology
; 158(8): 2139-2149.e14, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32092309
7.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Gastroenterology
; 158(8): 2123-2138.e8, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32044319
8.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Lancet
; 390(10114): 2779-2789, 2017 12 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29096949
9.
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.
Am J Gastroenterol
; 112(10): 1584-1592, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28071654
10.
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
Gastroenterology
; 146(4): 941-9, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24361468
11.
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
Gastroenterology
; 146(1): 110-118.e3, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24067881
12.
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
Am J Gastroenterol
; 109(11): 1771-80, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25155227
13.
Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
Gastroenterology
; 143(2): 365-74.e2, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22562021
14.
Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.
Am J Gastroenterol
; 112(6): 975, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28417993
15.
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
Gut
; 60(6): 780-7, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21209123
16.
Handling death as an intercurrent event in time to recovery analysis in COVID-19 treatment clinical trials.
Contemp Clin Trials
; 119: 106758, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35398251
17.
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease.
J Crohns Colitis
; 16(3): 444-451, 2022 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34546360
18.
Beneficial association of ß-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial.
Crit Care Med
; 39(5): 940-4, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21283007
19.
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.
Therap Adv Gastroenterol
; 13: 1756284820938960, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32733600
20.
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
Eur J Heart Fail
; 11(3): 304-11, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19158152